Pier Capital’s Vanda Pharmaceuticals VNDA Stock Holding History

Pier Capital’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	–	Sell	-486,995	Closed	-$5.33M	–	151
2013 Q3	$5.33M	Buy	+486,995	New	+$5.2M	0.75%	87

Other funds holding VNDA

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pier Capital's VNDA Position: Q4 2013 in Review

Pier Capital sold out of Vanda Pharmaceuticals (VNDA) in Q4 2013, closing a stake of 486,995 shares — an estimated $5.33M sold.

Pier Capital first reported a position in VNDA in Q3 2013 and held it in 1 quarter. The position peaked at $5.33M in Q3 2013. 86 funds tracked by Wall St. Rank hold VNDA as of Q4 2013.

Pier Capital reported no remaining Vanda Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
Pier Capital sold 486,995 Vanda Pharmaceuticals shares in Q4 2013, an estimated $5.33M.
Pier Capital first reported a position in Vanda Pharmaceuticals in Q3 2013 and held it in 1 quarter.
Pier Capital's Vanda Pharmaceuticals position peaked at $5.33M in Q3 2013.
86 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2013.

Based on Pier Capital's 13F filing for Q4 2013, filed 13 Feb 2014.